Testing immune cell therapy and chemotherapy for children whose brain tumor came back
Original title: CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people that looks mainly at side effects.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests immune cells built to attack a child's brain tumor.
Who this trial is for. This trial is for children with a brain tumor that has a marker called IL13Ralpha2. The tumor has come back or did not respond to earlier treatment. Children get chemotherapy, then immune cells made to target the tumor.
Where it stands. The trial is checking the side effects of this treatment. It has not reported results. The answer is not in yet.
What this means, and what it doesn't
What it could mean: The idea is that chemotherapy plus these immune cells may kill more tumor cells. A family whose child fits could ask their care team about this study.
What it doesn't mean: This does not mean the treatment works. A trial is a test, not proven care. Being in one is not a guarantee that it will help. It is not a promise of a cure.
Source: ClinicalTrials.gov, October 15, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.